🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26 Chicago is loaded this year. From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇 🩷 HR+ / HER2- DISEASE 1️⃣ persevERA BC (LBA1006) Giredestrant + palbociclib vs letrozole + palbociclib in 1L metastatic disease Despite missing the primary PFS endpoint, biomarker/subset analyses may define where oral SERDs still fit. 2️⃣ SERENA-6 (LBA1007) Camizestrant for emergent ESR1 mutations detected via ctDNA BEFORE radiographic progression Possibly the biggest ctDNA-guided endocrine strategy discussion of the meeting. 3️⃣ VIKTORIA-1 Gedatolisib + fulvestrant ± palbociclib after AI + CDK4/6i progression Huge unmet-need population. Post-CDK4/6 sequencing remains one of the biggest HR+ questions. 4️⃣ lidERA BC (Abstract 502) Adjuvant giredestrant in early ER+/HER2- disease Moving oral SERDs into curative-intent therapy. 5️⃣ FOURLIGHT-2 (Abstract 1042) Next-gen CDK4-selective inhibition with atirmociclib + letrozole Can we reduce neutropenia while preserving efficacy? 🔥 TNBC & ADC ERA 6️⃣ ASCENT-04 (LBA1000) Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in PD-L1+ mTNBC Could ADC + IO combinations become the frontline standard? 7️⃣ TROPION-Breast02 Dato-DXd vs chemotherapy in metastatic TNBC A major test of the “ADC-first” paradigm. 🎯 HER2+ & NEXT-GEN NEOADJUVANT PLATFORMS 8️⃣ KN026-004 (LBA660) Novel biparatopic HER2 antibody vs classic CLEOPATRA-style therapy Watch the pCR data carefully. 9️⃣ I-SPY 2.2 (LBA514) Rilvegostomig + T-DXd in high-risk HER2-negative disease IO + ADC combinations continue moving earlier. 🔟 DESTINY-Breast05 Update Long-term outcomes for T-DXd vs T-DM1 in residual HER2+ disease Which breast abstract are you watching most closely? #BCSM #OncoTwitter #ASCO26 #BreastCancer #MedEd @asco @myesmo @esmo_open @OncoAlert @OncBrothers
